Stocks to sell

Ocugen (NASDAQ:OCGN) has been one of 2021’s most volatile biotech companies. OCGN stock spiked from $2 to above $10 back in February after Ocugen announced that it was partnering with India’s Bharat Biotech on the latter’s Covid-19 vaccine.   Since then, Ocugen has been a roller coaster, dipping to $7 or $8 repeatedly before spiking up

Lucid Motors (NASDAQ:LCID) stock has some very impressive strengths, including the resume of its CEO and the positive reviews and  unmatched range of its Lucid Air electric vehicle. Source: Around the World Photos / Shutterstock.com These advantages, along with a large amount of press coverage, explain the current, gigantic valuation of LCID stock. That huge

Shares of struggling biotech, Progenity (NASDAQ:PROG), have been on quite the run of late. PROG stock has been a meme favorite and shot up more than 140% in value over the past couple of months. Moreover, the company has undergone a strategic transformation and appears to be laser focused on commercializing its product pipeline. However,

One of my stock assignments for this week was PROG stock. That’s the symbol for San Diego-based biotech Progenity (NASDAQ:PROG).  Source: Connect world / Shutterstock.com For a moment there, I got excited when I saw the stock on my coverage list. I love Progressive Insurance (NYSE:PGR). In November 2018, I put the property and casualty

“Sell the news” seemed to be the market’s response to AMC Entertainment’s (NYSE:AMC) latest earnings report. After the close on Nov. 8, the movie theater chain reported higher-than-expected revenue ($763 million versus $708 million consensus) and a narrower-than-expected per-share loss (44 cents versus 53 cents consensus), for the quarter ending Sept. 30. Yet, it did not

Not too long ago, Boeing (NYSE:BA) stock was trading at more than $400. But since early 2019, BA stock has shed more than 50% of its value. The aerospace giant has been hit hard by multiple crises in the past year, significantly weakening its balance sheet and safety reputation. Source: Marco Menezes / Shutterstock.com Moreover,

BlackBerry’s (NYSE:BB) lackluster operating performance indicates that it is unlikely to create long-term value. Though one of its core products, QNX, continues to gain traction, it’s hardly enough to generate meaningful returns for the company. Moreover, with its management’s spotty track record, it seems improbable that they would wisely allocate the proceeds from the sale

ContextLogic (NASDAQ:WISH) is set to announce its third-quarter earnings today under a new CFO. But there probably won’t be a lot to celebrate when the report is released. Ultimately, that means investing in WISH stock isn’t going to be worthwhile. Source: sdx15 / Shutterstock.com That said, ContextLogic will remain a popular choice for risk-tolerant retail

There are plenty of opportunities as the market heads higher. But despite the positive direction, there are still plenty of stocks to sell. First, let’s take a look at some of the positives. Unemployment numbers are going down and vaccinations are going up. The pandemic is losing its teeth, the global supply chain issues are

InvestorPlace columnist Larry Ramer recently argued that Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) and Qualcomm (NASDAQ:QCOM) would become potential buyers of BlackBerry (NYSE:BB) once they become more familiar with the company’s QNX operating system. Ramer believes that’s a good reason to buy BB stock.     Source: Shutterstock “[C]ompanies can’t hire enough cybersecurity experts to protect themselves from ruinous hacks,

Based on a very disturbing new report issued about Cassava (NASDAQ:SAVA), I have sold the vast majority of my shares of SAVA stock. And until the company refutes most or all of the allegations contained in the report, I believe that it’s too risky to hold more than a very small amount of Cassava’s shares.

Lucid Group (NASDAQ:LCID) stock has been on a tear. It’s up 59% in the past month and 317% year to date. Source: Around the World Photos / Shutterstock.com Much of that short-term run is because the company actually rolled 20 cars out of its factory and delivered them. I guess that this is where we are

Ocugen (NASDAQ:OCGN) stock didn’t move much on a recent announcement that it had applied to the FDA for a new emergency use authorization (EUA) for the Covaxin coronavirus vaccine. Source: shutterstock.com/PhotobyTawat This EUA is for people between the ages of two and 18, but the move is extremely unlikely to prevent OCGN stock from sliding in

With its massive price decline so far this year, is now the time to follow the crowd’s changing diagnosis on Teladoc (NYSE:TDOC)? Not so fast. TDOC stock may be down more than 25% year-to-date, and down about 50% from its all-time high of $308 per share. But despite this drop, and the fact it’s been trending

Virgin Galactic (NYSE:SPCE) has been on a bad downward spiral. From a recent peak of $55.91 on June 25, SPCE stock is now near a low point of $19.55. However, despite this, don’t act on the urge just yet to bargain hunt in this stock. Source: rafapress / Shutterstock.com I forewarned investors that this could

Ocugen (NASDAQ:OCGN) is a stock that I continue to be wrong about. Over the past month, OCGN stock has gained more than 80%, greatly testing my patience. The stock has fallen from the $17 mark it reached this morning, but is still higher than I expected last month. Source: shutterstock.com/PhotobyTawat In my last article about

If you’ve read my prior articles on Ocugen (NASDAQ:OCGN), you know full well my heavily bearish view about OCGN stock. What’s the story here? The company is trying to bring Covaxin, a Covid-19 vaccine candidate developed by India’s Bharat Biotech, to the U.S. and Canada. Source: shutterstock.com/PhotobyTawat So far, it’s made little progress obtaining Emergency

Microvision (NASDAQ:MVIS) specializes in providing a technology known as lidar, or light detection and ranging. There’s currently only a handful of ways to invest directly in the lidar market, and MVIS stock is one of them. Source: temp-64GTX/Shutterstock.com Just to give you a quick primer, lidar systems use laser beams to form a three-dimensional image of

Over the trailing year, a majority of my single-company opinions have been at least middle of the road for obvious reasons. Although I do have broader economic concerns, benchmark indices have proven resilient. So, my headline to consider exiting Novavax (NASDAQ:NVAX) stock might seem controversial. Source: Ascannio/Shutterstock.com However, I genuinely believe taking the green ink

Covid-19 vaccine giant Moderna (NASDAQ:MRNA) has been on a tear since the second quarter of 2020.  It has grown its top line by over 6,500% on a year-over-year basis due to rampant sales of its Covid-19 vaccine. As a consequence, it now trades at a whopping valuation hardly justified by its long-term outlook. The lack of